1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in
obesity among US adults 1999–2000 JAMA 2002;288:1723–7.
2. Mokdad AH, Serdula MK, Dietz WH, et al. The continuing epidemic of
obesity in the United States. JAMA 2000;284:1650–1 [letter].
3. Lewis CE, Jacobs DR Jr, McCreath H, et al. Weight gain continues in
the 1990s: 10-year trends in weight and overweight from the CARDIA study. Coronary Artery Risk
Development in Young Adults. Am J Epidemiol 2000;151:1172–81.
4. National Heart, Lung, and Blood Institute. Clinical Guidelines on
the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The
Evidence Report. NIH Publication No. 98-4083. Washington DC: National Institutes of
Health, 1998.
5. Emery EM, Schmid TL, Kahn HS, Filozof PP. A review of the association
between abdominal fat distribution, health outcome measures, and modifiable risk factors.
Am J Health Promot 1993;7:342–53 [review].
6. Brochu M, Poehlman ET, Ades PA. Obesity, body fat distribution, and
coronary artery disease. J Cardiopulm Rehabil 2000;20:96–108 [review.]
7. Fine JT, Colditz GA, Coakley EG, et al. A prospective study of weight
change and health-related quality of life in women. JAMA 1999;282:2136–42.
8. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality
in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097–105.
9. Miller WC. How effective are traditional dietary and exercise
interventions for weight loss? Med Sci Sports Exerc 1999;31:1129–34
[review].
10. Kassirer JP, Angell M. Losing weight—an ill-fated New Year's
resolution. N Engl J Med 1998;338:52–4.
11. Muls E, Kempen K, Vansant G, Saris W. Is weight cycling detrimental
to health? A review of the literature in humans. Int J Obes Relat Metab Disord
1995;19 Suppl 3:S46–S50 [review].
12. Brownell KD, Rodin J. Medical, metabolic, and psychological effects
of weight cycling. Arch Intern Med 1994;154:1325–30 [review].
13. Miller WC, Jacob AV. The health at any size paradigm for obesity
treatment: the scientific evidence. Obes Rev 2001;2:37–45 [review].
14. Salamone LM, Cauley JA, Black DM, et al. Effect of a lifestyle
intervention on bone mineral density in premenopausal women: a randomized trial. Am J Clin
Nutr 1999;70:97–103.
15. Armstrong J, Reilly JJ, Child Health Information Team. Breastfeeding
and lowering the risk of childhood obesity. Lancet 2002;359:2003–4.
16. Miller WC. How effective are traditional dietary and exercise
interventions for weight loss? Med Sci Sports Exerc 1999;31:1129–34
[review].
17. Kassirer JP, Angell M. Losing weight—an ill-fated New Year's
resolution. N Engl J Med 1998;338:52–4.
18. National Heart, Lung, and Blood Institute. Clinical Guidelines on
the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The
Evidence Report. NIH Publication No. 98-4083. Washington DC: National Institutes of
Health, 1998.
19. Astrup A, Grunwald GK, Melanson EL, et al. The role of low-fat diets
in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J
Obes Relat Metab Disord 2000;24:1545–52 [review].
20. Pirozzo S, Summerbell C, Cameron C, Glasziou P. Advice on low-fat
diets for obesity. Cochrane Database Syst Rev 2002;(2):CD003640 [review].
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood
Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
22. Potter J, ed. World Cancer Research Fund in association with American
Institute for Cancer Research. Food, Nutrition and the Prevention of Cancer: A Global
Perspective. Washington, DC: American Institute for Cancer Research; 1997.
23. Andersson I, Lennernas M, Rossner S. Meal pattern and risk factor
evaluation in one-year completers of a weight reduction program for obese men—the study.
J Intern Med 2000;247:30–8.
24. Shick SM, Wing RR, Klem ML, et al. Persons successful at long-term
weight loss and maintenance continue to consume a low-energy, low-fat diet. J Am Diet
Assoc 1998;98:408–13.
25. Wyatt HR, Grunwald GK, Mosca CL, et al. Long-term weight loss and
breakfast in subjects in the National Weight Control Registry. Obes Res
2002;10:78–82.
26. Westman EC, Yancy WS, Edman JS, et al. Effect of 6-month adherence to
a very low carbohydrate diet program. Am J Med 2002;113:30–6.
27. Bravata DM, Sanders L, Huang J, et al. Efficacy and safety of
low-carbohydrate diets: a systematic review. JAMA 2003;289:1837–50
[review].
28. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a
low-carbohydrate diet for obesity. N Engl J Med 2003;348:2082–90.
29. Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared
with a low-fat diet in severe obesity. N Engl J Med 2003;348:2074–81.
30. Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA. A randomized trial
comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight
and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab
2003;88:1617–23.
31. Sondike SB, Copperman N, Jacobson MS. Effects of a low-carbohydrate
diet on weight loss and cardiovascular risk factor in overweight adolescents. J
Pediatr2003;142:253–8.
32. Fleming RM. The effect of high-, moderate-, and low-fat diets on
weight loss and cardiovascular disease risk factors. Prev Cardiol
2002;5:110–8.
33. Fleming RM. The effect of high-protein diets on coronary blood flow.
Angiology 2000;51:817–26.
34. Eisenstein J, Roberts SB, Dallal G, Saltzman E. High-protein
weight-loss diets: are they safe and do they work? A review of the experimental and
epidemiologic data. Nutr Rev 2002;60:189–200 [review].
35. Layman DK, Boileau RA, Erickson DJ, et al. A reduced ratio of dietary
carbohydrate to protein improves body composition and blood lipid profiles during weight loss
in adult women. J Nutr 2003;133:411–7.
36. Skov AR, Toubro S, Ronn B, et al. Randomized trial on protein vs
carbohydrate in ad libitum fat reduced diet for the treatment of obesity. Int J Obes Relat
Metab Disord 1999;23:528–36.
37. Ball SD, Keller KR, Moyer-Mileur LJ. Prolongation of satiety after
low versus moderately high glycemic index meals in obese adolescents. Pediatrics
2003;111:488–94.
38. Dumesnil JG, Turgeon J, Tremblay A, et al. Effect of a low-glycaemic
index–low-fat–high protein diet on the atherogenic metabolic risk profile of
abdominally obese men. Br J Nutr 2001;86:557–68.
39. Roberts SB. High-glycemic index foods, hunger, and obesity: is there
a connection? Nutr Rev 2000;58:163–9 [review].
40. Raben A. Should obese patients be counselled to follow a low
glycaemic diet? No. Obesity Rev 2002;3:245–56 [review].
41. Slabber M, Barnard HC, Kuyl JM, et al. Effects of a
low-insulin-response, energy-restricted diet on weight loss and plasma insulin concentrations
in hyperinsulinemic obese females. Am J Clin Nutr 1994;60:48–53.
42. Spieth LE, Harnish JD, Lenders CM, et al. A low-glycemic index diet
in the treatment of pediatric obesity. Arch Pediatr Adolesc Med
2000;154:947–51.
43. Burton-Freeman B. Dietary fiber and energy regulation. J
Nutr 2000;130(2S Suppl):272S-275S [review].
44. Saltzman E, Roberts SB. Soluble fiber and energy regulation. Current
knowledge and future directions. Adv Exp Med Biol 1997;427:89–97 [review].
45. Howarth NC, Saltzman E, Roberts SB. Dietary fiber and weight
regulation. Nutr Rev 2001;59:129–39 [review].
46. Randolph TG. Masked food allergy as a factor in the development and
persistence of obesity. J Lab Clin Med 1947;32:1547.
47. Muls E, Kempen K, Vansant G, et al. Is weight cycling detrimental to
health? A review of the literature in humans. Int J Obes
1995;19(3):S46–S50.
48. Wadden TA, Berkowitz RI, Sarwer DB, et al. Benefits of lifestyle
modification in the pharmacologic treatment of obesity. A randomized trial. Arch Intern
Med 2001;161:218–27.
49. Votruba SB, Horvitz MA, Schoeller DA. The role of exercise in the
treatment of obesity. Nutrition 2000;16:179–88.
50. Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25
years of weight-loss research using diet, exercise or diet plus exercise intervention. Int
J Obes Relat Metab Disord 1997;21:941–7.
51. Pritchard JE, Nowson CA, Wark JD. A worksite program for overweight
middle-aged men achieves lesser weight loss with exercise than with dietary change. J Am
Diet Assoc 1997 Jan;97:37–42.
52. Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25
years of weight-loss research using diet, exercise or diet plus exercise intervention. Int
J Obes Relat Metab Disord 1997;21:941–7.
53. Pavlou KN, Krey S, Steffee WP. Exercise as an adjunct to weight loss
and maintenance in moderately obese subjects. Am J Clin Nutr 1989;49(5
Suppl):1115–23.
54. Wing RR, Hill JO. Successful weight-loss maintenance. Annu Rev
Nutr 2001;21:323–41.
55. Racette SB, Schoeller DA, Kushner RF, Neil KM. Exercise enhances
dietary compliance during moderate energy restriction in obese women. Am J Clin Nutr
1995;62:345–9.
56. Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25
years of weight-loss research using diet, exercise or diet plus exercise intervention. Int
J Obes Relat Metab Disord 1997;21:941–7.
57. Cummings S, Parham ES, Strain GW; American Dietetic Association.
Position of the American Dietetic Association: weight management. J Am Diet Assoc
2002 Aug;102:1145–55.
58. Jakicic JM, Clark K, Coleman E, et al. American College of Sports
Medicine position stand. Appropriate intervention strategies for weight loss and prevention of
weight regain for adults. Med Sci Sports Exerc 2001;33:2145–56 [review].
59. Riebe D, Greene GW, Ruggiero L, et al. Evaluation of a
healthy-lifestyle approach to weight management. Prev Med 2003;36:45–54.
60. National Task Force on the Prevention and Treatment of Obesity.
Dieting and the Development of Eating Disorders in Overweight and Obese Adults. Arch
Intern Med 2000;160:2581–9.
61. Pi-Sunyer FX. Obesity. In Shils ME, Olson JA, Shike M, Ross AC, eds.
ModernNutrition in Health and Disease, 9th ed. Baltimore: Williams and Wilkins,
1999,1410.
62. Stanko RT, Tietze DL, Arch JE. Bodycomposition, energy utilization,
and nitrogen metabolism with a 4.25-MJ/d low-energy dietsupplemented with pyruvate. Am J
Clin Nutr 1992;56:630–5.
63. Stanko RT, Reynolds HR, Hoyson R, etal. Pyruvate supplementation of a
low-cholesterol, low-fat diet: Effects on plasma lipidconcentration and body composition in
hyperlipidemic patients. Am J Clin Nutr1994;59:423–7.
64. KalmanD, Colker CM, Wilets I, et al. The effects of pyruvate
supplementation on body composition inoverweight individuals. Nutrition
1999;15:337–40.
65. Kalman D, Colker CM,Stark S, et al. Effect of pyruvate
supplementation on body composition and mood. Curr TherRes 1998;59:793–802.
66. Kreider R, Koh P, Ferreira M, et al.Effects of pyruvate
supplementation during training on body composition & metabolicresponses to exercise.
Med Sci Sports Exerc 1998;30:S62 [abstract].
67. Ivy JL, Cortez MY, Chandler RM, et al. Effects of pyruvate on the
metabolismand insulin resistance of obese Zucker rats. Am J Clin
Nutr1994;59:331–7.
68. Ceci F, Cangiano C, Cairella M, et al.The effects of oral
5-hydroxytryptophan administration on feeding behavior in obese adultfemale subjects. J
Neural Transm 1989;76:109–17.
69. Cangiano C, Ceci F,Cascino A, et al. Eating behavior and adherence to
dietary prescriptions in obese adultsubjects treated with 5-hydroxytryptophan. Am J Clin
Nutr1992;56:863–7.
70. Cangiano C, Ceci F, Cairella M, et al. Effects of 5-hydroxytryptophan
on eating behavior and adherence to dietary prescriptions in obese adultsubjects. Adv Exp
Med Biol 1991;294:591–3.
71. Cangiano C, Ceci F, Cascino A,et al. Eating behavior and adherence to
dietary prescriptions in obese adult subjects treatedwith 5-hydroxytryptophan. Am J Clin
Nutr 1992;56:863–7.
72. Cangiano C, Laviano A,Del Ben M, et al. Effects of oral
5-hydroxy-tryptophan on energy intake and macronutrientselection in non-insulin dependent
diabetic patients. Int J Obes Relat Metab Disord1998;22:648–54.
73. Kalman DS, Colker CM, Swain MA, et al. A randomized, double-blind,
placebo controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy overweight
adults. Curr Ther Res 2000;61:435–42.
74. Ransone J, Neighbors K, Lefavi R, Chromiak J. The effect of
beta-hydroxy beta-methylbutyrate on muscular strength and body composition in collegiate
football players. J Strength Cond Res 2003;17:34–9.
75. Kreider R, Ferreira M, Wilson M, et al. Effects of calcium beta-HMB
supplementation with or without creatine during training on body composition alterations.
FASEB J 1997;11:A374 [abstract].
76. Slater G, Jenkins D, Logan P, et al. Beta-hydroxy-beta-methylbutyrate
(HMB) supplementation does not affect changes in strength or body composition during
resistance training in trained men. Int J Sport Nutr Exerc Metab 2001;11:384–96.
77. Kreider RB, Ferreira M, Wilson M, Almada AL. Effects of calcium
beta-hydroxy-beta-methylbutyrate (HMB) supplementation during resistance-training on markers
of catabolism, body composition and strength. Int J Sports Med 1999;20:503–9.
78. Slater GJ, Jenkins D. Beta-hydroxy-beta-methylbutyrate (HMB)
supplementation and the promotion of muscle growth and strength. Sports Med
2000;30:105–16 [review].
79. Vukovich MD, Stubbs NB, Bohlken RM. Body composition in 70-year-old
adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults.
J Nutr 2001;131:2049–52.
80. Gallagher PM, Carrithers JA, Godard MP, et al.
Beta-hydroxy-beta-methylbutyrate ingestion, Part I: effects on strength and fat free mass. Med
Sci Sports Exerc 2000;32:2109–15.
81. Zemel MB, Thompson W, Milstead A, et al. Calcium and dairy
acceleration of weight and fat loss during energy restriction in obese adults. Obes
Res 2004;12:582–90.
82. Shapses SA, Heshka S, Heymsfield SB. Effect of calcium
supplementation on weight and fat loss in women. J Clin Endocrinol Metab
2004;89:632–7.
83. Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces
body fat in healthy exercising humans. J Int Med Res 2001;29:392–6.
84. Mougios V, Matsakas A, Petridou A, et al. Effect of supplementation
with conjugated linoleic acid on human serum lipids and body fat. J Nutr Biochem
2001;12:585–94.
85. Zambell KL, Keim NL, Van Loan MD, et al. Conjugated linoleic acid
supplementation in humans: effects on body composition and energy expenditure. Lipids
2000;35:777–82.
86. Riserus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA)
reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic
syndrome: a randomised controlled trial. Int J Obes Relat Metab Disord
2001;25:1129–35.
87. Smedman A, Vessby B. Conjugated linoleic acid supplementation in
humans–metabolic effects. Lipids 2001;36:773-81.
88. Blankson H, Stakkestad JA, Fagertun H, et al. Conjugated linoleic
acid reduces body fat mass in overweight and obese humans. J Nutr
2000;130:2943–8.
89. Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic
acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr
2007;85:1203–11.
90. Kreider RB, Ferreira MP, Greenwood M, et al. Effects of conjugated
linoleic acid supplementation during resistance training on body composition, bone density,
strength, and selected hematological markers. J Strength Cond Res
2002;16:325–34.
91. Marquette CJ Jr. Effects of bulk producing tablets on hunger
intensity in dieting patients. Obes Bariatr Med 1976;5:84–8.
92. Rossner S, von Zweigbergk D, Ohlin A, Ryttig K. Weight reduction with
dietary fibre supplements. Acta Med Scand 1987;222:83–8.
93. Ryttig KR, Tellnes G, Haegh L, et al. A dietary fibre supplement and
weight maintenance after weight reduction: a randomized, double-blind, placebo-controlled
long-term trial. Int J Obes 1989;13:165–71.
94. Solum TT, Ryttig KR, Solum E, Larsen S. The influence of a high-fibre
diet on body weight, serum lipids and blood pressure in slightly overweight persons. A
randomized, double-blind, placebo-controlled investigation with diet and fibre tablets
(DumoVital). Int J Obes1987;11 Suppl 1:67–71.
95. Hylander B, Rössner S. Effects of dietary fiber intake before
meals on weight loss and hunger in a weight-reducing club. Acta Med Scand
1983;213:217–20.
96. Biancardi G, Palmiero L, Ghirardi PE. Glucomannan in the treatment of
overweight patients with osteoarthritis. Curr Ther Res 1989;46:908–12.
97. Vita PM, Restelli A, Caspani P, Klinger R. Chronic use of glucomannan
in the dietary treatment of severe obesity. Minerva Med 1992;83:135–9 [in
Italian].
98. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese
patients: a clinical study. Int J Obes 1984;8:289–93.
99. Livieri C, Novazi F, Lorini R. The use of highly purified
glucomannan-based fibers in childhood obesity. Pediatr Med Chir 1992;14:195–8
[in Italian].
100. Lowenstein JM. Effect of (-)-hydroxycitrate on fatty acid synthesis
by rat liver invivo. J Biol Chem 1971;246:629–32.
101. Triscari J, Sullivan AC.Comparative effects of (-)-hydroxycitrate
and (+)-allo-hydroxycitrate on acetyl CoAcarboxylase and fatty acid and cholesterol synthesis
in vivo. Lipids1977;12:357–63.
102. Cheema-Dhadli S, Harlperin ML, LeznoffCC. Inhibition of enzymes
which interact with citrate by (-)hydroxycitrate and1,2,3,-tricarboxybenzene. Eur J
Biochem 1973;38:98–102.
103. Sullivan AC,Hamilton JG, Miller ON, et al. Inhibition of lipogenesis
in rat liver by (-)-hydroxycitrate.Arch Biochem Biophys 1972;150:183–90.
104. Greenwood MRC, Cleary MP, Gruen R, etal. Effect of
(-)-hydroxycitrate on development of obesity in the Zucker obese rat. Am JPhysiol
1981;240:E72–8.
105. Sullivan AC, Triscari J. Metabolicregulation as a control for lipid
disorders. Am J Clin Nutr1977;30:767–76.
106. Sullivan AC, Triscari J, Hamilton JG, et al. Effect
of(-)-hydroxycitrate upon the accumulation of lipid in the rat: I. Lipogenesis.
Lipids1974;9:121–8.
107. Sullivan AC, Triscari J, Hamilton JG, et al. Effect
of(-)-hydroxycitrate upon the accumulation of lipid in the rat: II. Appetite.
Lipids1974;9:129–34.
108. Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia
(hydroxycitricacid) as a potential antiobesity agent: a randomized controlled trial.
JAMA1998;280:1596–600.
109. Martinet A, Hostettmann K, Schultz Y.Thermogenic effects of
commercially available plant preparations aimed at treating humanobesity.
Phytomedicine 1999;6:231–8.
110. Mattes RD, BormannL. Effects of (-)-hydroxycitric acid on appetitive
variables. Physiol Behav2000;71:87–94.
111. Marshall JJ, Lauda CM. Purification and properties of phaseolamin,
an inhibitor of alpha-amylase, from the kidney bean, Phaseolus vulgaris. J Biol Chem
1975;250:8030-7.
112. Choudhury A, Maeda K, Murayama R, DiMagno EP. Character of a wheat
amylase inhibitor preparation and effects on fasting human pancreaticobiliary secretions and
hormones. Gastroenterology 1996;111:1313-20.
113. Bo-Linn GW, Santa Ana CA, Morawski SG, Fordtran JS.
Starchblockers—their effect on calorie absorption from a high-starch meal. N Engl
JMed 1982;307:1413–6.
114. Hollenbeck CB, Coulston AM, Quan R, et al.Effects of a commercial
starch blocker preparation on carbohydrate digestion and absorption: in vivo and in vitro
studies. Am J Clin Nutr 1983;38:498–503.
115. GarrowJS, Scott PF, Heels S, et al. A study of starch blockers in
man using 13C-enriched starch as a tracer. Hum Nutr Clin Nutr
1983;37:301–5.
116. CarlsonGL, Li BU, Bass P, Olsen WA. A bean alpha-amylase inhibitor
formulation (starchblocker) is ineffective in man. Science 1983;219:393–5.
117. BruggeWR, Rosenfeld MS. Impairment of starch absorption by a potent
amylase inhibitor.Am J Gastroenterol 1987;82:718–22.
118. Boivin M, Zinsmeister AR, Go VL,DiMagno EP. Effect of a purified
amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. Mayo
Clin Proc 1987;62:249–55.
119. LayerP, Carlson GL, DiMagno EP. Partially purified white bean
amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase
inhumans. Gastroenterology 1985;88:1895–902.
120. Becher EW, Jakober B, Luft D, et al.Clinical and biochemical
evaluations of the alga spirulina with regard to its application inthe treatment of obesity. A
double-blind cross-over study. Nutr Rep Intl1986;33:565–73.
121. Gades MD, Stern JS. Chitosan supplementation does not affect fat
absorption in healthy males fed a high-fat diet, a pilot study. Int J Obes Relat
Metab Disord 2002;26:119–22.
122. Guerciolini R, Radu-Radulescu L, Boldrin M, et al. Comparative
evaluation of fecal fat excretion induced by orlistat and chitosan. Obes Res
2001;9:364–7.
123. Zahorska-Markiewicz B, Krotkiewski M, Olszanecka-Glinianowicz M,
Zurakowski A. Effect of chitosan in complex management of obesity. Pol Merkuriusz Lek
2002;13:129–32 [in Polish].
124. Kaats GR, Michalek JE, Preuss HG. Evaluating efficacy of a chitosan
product using a double-blinded, placebo-controlled protocol. J Am Coll Nutr
2006;25:389–94.
125. Ho SC, Tai ES, Eng PH, et al. In the absence of dietary
surveillance, chitosan does not reduce plasma lipids or obesity in hypercholesterolaemic obese
Asian subjects. Singapore Med J 2001;42:006–10.
126. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind
trial of chitosan for body weight reduction. Eur J Clin Nutr
1999;53:379–81.
127. Muzzarelli RA. Clinical and biochemical evaluation of chitosan for
hypercholesterolemia and overweight control. EXS 1999;87:293–304 [review].
128. Anderson RA. Effects of chromium on body composition and weight
loss. Nutr Rev 1998;56:266–70.
129. Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound
chromium supplementation on body composition in overweight African-American women. Diabetes
Obes Metab 1999;1:331-7.
130. Bahadori B, Wallner S, Schneider H, et al. Effect of chromium yeast
and chromium picolinate on body composition of obese, non-diabetic patients during and after a
formula diet. Acta Med Austriaca 1997;24:185–7
131. Trent LK, Thieding-Cancel D. Effects of chromiumpicolinate on body
composition. J Sports Med Phys Fitness 1995;35:273–80
132. Volpe SL, Huang HW, Larpadisorn K, Lesser II. Effect of chromium
supplementation and exercise on body composition, resting metabolic rate and selected
biochemical parameters in moderately obese women following an exercise program. J Am Coll
Nutr 2001;20:293–306.
133. Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing
body weight: meta-analysis of randomized trials. Int J Obes Relat Metab Disord
2003;27:522–9.
134. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months
treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex
steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol
1998;49:421–32.
135. Nestler JE, Barlascini CO, Clore JN, Blackard WG.
Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not
alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988;66:57–61.
136. Percheron G, Hogrel JY, Denot-Ledunois S, et al. Effect of 1-year
oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle
function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med
2003;163:720–7.
137. Wallace MB, Lim J, Cutler A, Bucci L. Effects of
dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc
1999;31:1788–92.
138. Brown GA, Vukovich MD, Sharp RL, et al. Effect of oral DHEA on serum
testosterone and adaptations to resistance training in young men. J Appl Physiol
1999;87:2274–83.
139. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months
treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex
steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol
(Oxf) 1998;49:421–32.
140. Vogiatzi MG, Boeck MA, Vlachopapadopoulou E, et al.
Dehydroepiandrosterone in morbidly obese adolescents: effects on weight, body composition,
lipids, and insulin resistance. Metabolism 1996;45:1011–5.
141. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose
of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab
1994;78:1360–7.
142. Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on
endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab
1990;71:696–704.
143. Usiskin KS, Butterworth S, Clore JN, et al. Lack of effect of
dehydroepiandrosterone in obese men. Int J Obes 1990;14:457–63.
144. Kovacs EM, Westerterp-Plantenga MS, Saris WH, et al. The effect of
addition of modified guar gum to a low-energy semisolid meal on appetite and body weight loss.
Int J Obes Relat Metab Disord 2001;25:307–15.
145. Beattie VA, Edwards CA, Hosker JP, et al. Does adding fibre to a low
energy, high carbohydrate, low fat diet confer any benefit to the management of newly
diagnosed overweight type II diabetics? Br Med J (Clin Res Ed)
1988;296:1147–9.
146. Pasman WJ, Westerterp-Plantenga MS, Muls E, et al. The effectiveness
of long-term fibre supplementation on weight maintenance in weight-reduced women. Int J
Obes Relat Metab Disord 1997;21:548–55.
147. He Z-Q, Phone ZS. Body weight reductionin adolescents by a
combination of measures including using L-carnitine. Acta NutrimentaSinica
1997;19.
148. VillaniRG, Gannon J, Self M, Rich PA. L-Carnitine supplementation
combined with aerobictraining does not promote weight loss in moderately obese women. Int
J SportNutrExerc Metab 2000;10:199–207.
149. Bhathena SJ, Velasquez MT. Beneficial role ofdietary phytoestrogens
in obesity and diabetes. Am J Clin Nutr2002;76:1191–201[review].
150. Allison DB, Gadbury G, Schwartz LG, et al. Anovel soy-based meal
replacement formula for weight loss among obeseindividuals: a randomized controlled clinical
trial. Eur J Clin Nutr2003;57:514–22.
151. Bosello O,Cominancini L, Zocca I, et al. Short- and long-term
effects of hypocaloric dietscontaining proteins of different sources on plasma lipids and
apoproteins ofobese subjects. Ann Nutr Metab 1988; 32:206–14.
152. Yamashita T, Sasahara T, Pomeroy SE, et al. Arterial compliance,
bloodpressure, plasma leptin, and plasma lipids in women are improved with weight reduction
equally with a meat-based diet and a plant-based diet.
Metabolism1998;47:1308–14.
153. Jenkins DJ, Wolever TM, Spiller G, et al. Hypocholesterolemic effect
ofvegetable protein in a hypocaloric diet. Atherosclerosis 1989;78:99–107.
154. Hall WL, Millward DJ, Long SJ, MorganLM. Casein and whey exert
different effects on plasma amino acid profiles, gastrointestinalhormone secretion and
appetite. Br J Nutr 2003;89:239–48.
155. Demling RH, DeSanti L. Effect of a hypocaloric diet, increased
protein intake andresistance training on lean mass gains and fat mass loss in overweight
police officers.AnnNutr Metab 2000;44:21–9.
156. Yoshioka M, Doucet E, Drapeau V, et al. Combined effects of red
pepper and caffeine consumption on 24 h energy balance in subjects given free access to foods.
Br J Nutr 2001;85:203–11.
157. Yoshioka M, St-Pierre S, Drapeau V, et al. Effects of red pepper on
appetite and energy intake. Br J Nutr 1999;82:115–23.
158. Yoshioka M, Doucet E, Drapeau V, et al. Combined effects of red
pepper and caffeine consumption on 24 h energy balance in subjects given free access to foods.
Br J Nutr 2001;85:203–11.
159. Yoshioka M, St-Pierre S, Suzuki M, Tremblay A. Effects of red pepper
added to high-fat and high-carbohydrate meals on energy metabolism and substrate utilization
in Japanese women. Br J Nutr 1998;80:503–10.
160. Yoshioka M, Lim K, Kikuzato S, et al. Effects of red-pepper diet on
the energy metabolism in men. J Nutr Sci Vitaminol (Tokyo) 1995;41:647–56.
161. Dulloo AG, Seydoux J, Girardier L, et al. Green tea and
thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity.
Int J Obes Relat Metab Disord 2000;24:252–8.
162. Juhel C, Armand M, Pafumi Y, et al. Green tea extract (AR25)
inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro. J Nutr
Biochem 2000;11:45–51.
163. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract
rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat
oxidation in humans. Am J Clin Nutr 1999;70:1040–5.
164. Chantre P, Lairon D. Recent findings of green tea extract AR25
(Exolise) and its activity for the treatment of obesity. Phytomedicine
2002;9:3–8.
165. Nagao T, Komine Y, Soga S, et al. Ingestion of a tea rich in
catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am J
Clin Nutr 2005;81:122–9.
166. Phytopharm. Successful completion of proof of principle
clinical study of P57 for obesity [press release] 2001 Dec 5 [cited 2005 Sep 20]. Available
from URL: http://www.phytopharm.co.uk/press/P57%20Third%20Stage%20final.htm.
167. Mosqueda-Garcia R, Fernandez-Violante R, Tank J, et al. Yohimbine in
neurally mediated syncope. Pathophysiological implications. J Clin Invest
1998;102:1824–30.
168. Goldberg MR, Robertson D. Yohimbine: a pharmacological probe for the
study of the alpha 2-adrenoceptor.Pharmacol Rev 1983;35:143–80.
169. Galitzky J, Taouis M, Berlan M, et al. Alpha 2-antagonist compounds
and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy
male volunteers. Eur J Clin Invest 1988;18:587–94.
170. Zahorska-Markiewicz B, Kucio C, Piskorska D. Adrenergic control of
lipolysis and metabolic responses in obesity. Horm Metab Res 1986;18:693–7.
171. Kucio C, Jonderko K, Piskorska D. Does yohimbine act as a slimming
drug? Isr J Med Sci 1991;27:550–6.
172. Berlin I, Crespo-Laumonnier B, Turpin G, Puech AJ. The alpha-2
adrenoceptor antagonist yohimbine does not facilitate weight loss but blocks adrenaline
induced platelet aggregation in obese subjects. Therapie 1989;44:301 [letter].
173. Sax L. Yohimbine does not affect fat distribution in men. Int J
Obes 1991;15:561–5.
174. Colker CM, Kalman DS, Torina GC, et al. Effects of Citrus
aurantium extract, caffeine, and St. John’s wort on body fat, lipid levels, and
mood states in overweight adults. Curr Ther Res 1999;60:145–53.
175. Calapai G, Firenzuoli F, Saitta A, et al. Antiobesity and
cardiovascular toxic effects of Citrus aurantium extracts in the rat: A preliminary
report. Fitoterapia 1999;70:586–92.
176. Bone K. Clinical Applications of Ayurvedic and Chinese
Herbs. Warwick, Queensland, Australia: Phytotherapy Press, 1996, 103–7.
177. Leung A, Foster S. Encyclopedia of Common Natural Ingredients
Used in Food, Drugs, and Cosmetics, 2d ed. NewYork: John Wiley & Sons, 1996,
293–4.
178. Astrup A, Breum L, Toubro S, et al. The effect and safety of an
ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on
an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord
1992;16:269–77.
179. Antonio J, Colker CM, Torina GC, et al. Effects of a standardized
guggulsterone phosphate supplement on body composition in overweight adults: A pilot study.
Curr Ther Res 1999;60:220–7.